Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study

Background: Federal small business awards from the National Institutes of Health fund neurosurgical devices and procedural technologies, but how often the specific funded capability reaches human use is unknown. We determined how often these technologies had documented human implementation and in which settings. Methods: We assembled a retrospective public-source cohort of technologies supported by Small Business Innovation Research and Small Business Technology Transfer awards from fiscal years 2005–2020 by keyword filtering and funded-purpose review. Confirmation required living-human use of the funded capability or a supported direct extension after a qualifying same-technology award, with public evidence by October 8, 2026. Exploratory comparisons examined program, observed phase, award era, and cumulative support. A 500-family random sample assessed screening omissions. Results: The cohort comprised 209 technologies, 221 award families, and 453 applications receiving $206,825,343. Human implementation was documented for 31/209 technologies (14.8%; Wilson 95% confidence interval, 10.7%–20.3%); evidence was not located for 156 and was indeterminate for 22. Confirmed settings were neurosurgical-scope care (26), other clinical care (2), mixed surgical cohorts (1), and nonclinical human evaluation (2). Confirmation was more frequent with observed Phase II support than Phase I only (21/98 vs 10/111; difference, 12.4 percentage points; company-component bootstrap 95% confidence interval, 2.8–22.4). None of four conventional tests met a Holm-adjusted .05 threshold. Screening scenarios estimated 40–76 omitted families. Conclusion: Approximately one in seven included technologies had documented human implementation. Linking individual awards to implemented capabilities provides an empirical benchmark for early neurosurgical translation and a practical foundation for tracking subsequent clinical evaluation.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.26368058
Primary Topic
Health and Medical Research Impacts
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study

Anand V. Germanwala, Shiau-Sing K Ciecierska, Abhinav Bachu, Y J Ahn et al.
medRxiv
Health and Medical Research Impacts
preprint

Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study

Anand V. Germanwala, Shiau-Sing K Ciecierska, Abhinav Bachu, Y J Ahn, Raghav Rajesh
preprint en

Abstract

Background: Federal small business awards from the National Institutes of Health fund neurosurgical devices and procedural technologies, but how often the specific funded capability reaches human use is unknown. We determined how often these technologies had documented human implementation and in which settings. Methods: We assembled a retrospective public-source cohort of technologies supported by Small Business Innovation Research and Small Business Technology Transfer awards from fiscal years 2005–2020 by keyword filtering and funded-purpose review. Confirmation required living-human use of the funded capability or a supported direct extension after a qualifying same-technology award, with public evidence by October 8, 2026. Exploratory comparisons examined program, observed phase, award era, and cumulative support. A 500-family random sample assessed screening omissions. Results: The cohort comprised 209 technologies, 221 award families, and 453 applications receiving $206,825,343. Human implementation was documented for 31/209 technologies (14.8%; Wilson 95% confidence interval, 10.7%–20.3%); evidence was not located for 156 and was indeterminate for 22. Confirmed settings were neurosurgical-scope care (26), other clinical care (2), mixed surgical cohorts (1), and nonclinical human evaluation (2). Confirmation was more frequent with observed Phase II support than Phase I only (21/98 vs 10/111; difference, 12.4 percentage points; company-component bootstrap 95% confidence interval, 2.8–22.4). None of four conventional tests met a Holm-adjusted .05 threshold. Screening scenarios estimated 40–76 omitted families. Conclusion: Approximately one in seven included technologies had documented human implementation. Linking individual awards to implemented capabilities provides an empirical benchmark for early neurosurgical translation and a practical foundation for tracking subsequent clinical evaluation.

medRxiv
Loyola University Chicago (US)
Health and Medical Research Impacts
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon